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Summary 
Vascular cell adhesion molecule-1 (VCAM-1)  is induced on endothdial cells by inflammatory 
cytokines, and binds mononuclear leukocytes through the integrin very late antigen-4 (VLA-4) 
(o14B1). This adhesion pathway has been implicated in a diverse  group of physiological  and 
pathological processes, including B cell development, leukocyte activation and recruitment to 
sites of inflammation, atherosderosis, and tumor cell metastasis.  The major form of VCAM-1 
(VCAM-7D) has seven extracelkdar immunoglobulin (Ig)-like domains, of which the three NHz- 
terminal domains (domains 1-3) are similar in amino acid sequence to domains 4-6. By functional 
analysis of VCAM-7D rdative to VCAM-6D (a minor 6-domain form of VCAM-1 in which 
domain 4 is deleted because of alternative  splicing), and chimeric constructs between VCAM-1 
and its structural relative intercellular  adhesion molecule-1 (ICAM-1), we show that either the 
first or the homologous fourth domain of VCAM-1 is required for VLA-4-dependent adhesion. 
Either of these binding sites can function in the absence of the other. When both are present, 
cell binding activity is increased relative to monovalent forms of the molecule. The homologous 
binding regions appear to have originated by internal duplication of a portion of a monovalent 
ancestral  gene, before the mammalian radiation.  Thus VCAM-1  exemplifies  evolution of a 
functionally bivalent cell--cell adhesion molecule by intergenic duplication. We have also produced 
a new class of anti-VCAM-1 monoclonal antibodies that block domain 4-dependent adhesion, 
and demonstrate that both binding sites participate in the adhesion function of VCAM-1 on 
endothelial cells in vitro. Therefore both sites must be blocked in clinical,  animal, or in vitro 
studies depending on the use of anti-VCAM-1 antibodies to inactivate the VCAM-1/VLA4 adhesion 
pathway. 
V 
~ascular  cell  adhesion  molecule-1  (VCAM-1) 1  (also 
known as inducible cell adhesion molecule-110 [INCAM- 
110]) was first identified as an adhesion molecule induced on 
endothelial cells by inflammatory cytokines (TNF and II-1) 
and LPS (1, 2).  It binds to cells bearing the integrin very 
late antigen (VLA-4)  (o~d31), including T  and B lympho- 
cytes, monocytes, basophils, and eosinophils, but not neu- 
trophils, and participates in recruitment of these cells from 
the bloodstream to areas of infection and inflammation (3-7). 
The VCAM-1/VLA-4 adhesion pathway is important in a 
number of physiological and pathological processes. Although 
VLA-4 is normally restricted to hematopoietic lineages,  it 
is found on melanoma cell lines, and thus VCAM-1 has been 
suggested to participate in metastasis of such tumors (1). In 
vivo, VCAM-1 is  found on areas of arterial  endothelium 
1 Abbreviations used in this paper: ELAM-I, endothelial leukocyte adhesion 
molecule-I; HUVEC, human umbilical vein endothelial cells; ICAM-1, 
intercellular adhesion molecule-I, VCAM-1, vascular cell adhesion mole- 
cub-l, VLA-4, very late antigen-4. 
representing early atherosderotic plaques in a rabbit model 
system (8). It is also found on follicular dendritic cells in normal 
human lymph nodes (9), and on bone marrow stromal cells 
in the mouse (10), where it plays a role in B cell development. 
VCAM-1 belongs to the Ig superfamily. The major form 
on endothelial cells, VCAM-TD, has seven Ig homology units 
or domains. Domains 4-6 are similar in amino acid sequence 
to domains 1-3, suggesting an intergenic duplication event 
in the evolutionary history of the gene. There is also a minor 
6-domain form (VCAM-6D) generated by alternative splicing, 
in which the fourth domain is deleted (2, 11-15). Biological 
significance of this minor form is unknown. 
It has been shown previously that the first three domains 
of VCAM-1 can bind to VLA-4, when fused to an Ig con- 
stant region (16). The first three domains of VCAM-1 iso- 
lated by proteolytic cleavage, and the first two domains of 
VCAM-1 produced as a soluble recombinant molecule, also 
support both VLA-4-dependent adhesion and the binding 
of blocking mAb 4B9 when bound to plastic (R. B. Pepinsky, 
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test for other regions of VCAM-1 involved in cell adhesion. 
In an effort to avoid structural instability caused by deletions 
of portions of the protein,  we made chimeric constructs, 
replacing portions of the VCAM-1 molecule with analogous 
regions of its closest  structural relative,  intercellular adhe- 
sion molecule-1  (ICAM-1), and tested transfectants for ex- 
pression,  cell binding, and antibody binding. We find that 
binding of VLA-4 to VCAM-1 can occur via two separate 
sites, one requiring domain 1, and the other requiring do- 
main 4. We have produced a novel group of anti-VCAM-1 
mAbs that bind to the alternately spliced domain 4. Two of 
these antibodies can inhibit domain 4-dependent cell adhe- 
sion, and can inhibit cell binding to VCAM-1 on cultured 
endothelial cells, implying that binding through domain 4 
is an important functional component of the VLA-4/VCAM-1 
interaction in vivo. 
Materials and Methods 
Antibodies and Cells.  Previously  described mAbs used were anti- 
CD18, 60.3 (17); anti-VLA-4, HP1/2 (18); and anti-VCAM-1, 4B9 
(19). GE4, GH12, and EDll are IgG1 mAbs made from mice im- 
munized with recombinant soluble VCAM-7D (20), and will be 
described in detail elsewhere (C. D. Benjamin and I. Dougas, un- 
published data). Polyclonal  rabbit anti-VCAM-1 serum was made 
by inoculating  rabbits with  recombinant  soluble VCAM-TD. 
Human umbilical vein endothelial cells (HUVECs), COS7, and 
leukocytic ceils were cultured as previously described (2). 
Plasmid Constructions.  Aliquots of the parent plasmids VCAM- 
1E11/CDM8 (7 domain) (13) or VCAM41/CDM8 (6 domain) (2, 
13) were digested  by restriction  endonucleases  (see Fig. 2) and agarose 
gd purified. ICAM-1 inserts were made by PCR, using as tem- 
plate an ICAM-1/CDM8  plasmid isolated from the endothelial 
cDNA library previously described (2), probed with oligonucleo- 
tides based on the published sequence of ICAM-1 (21, 22). The 
PCR primers were designed as follows: 
EcoR5 
P-l, 5' TCT AGA TAT CTT CTG CCC CGG GAG GCT CCG TGC TG Y 
S  R  Y  L  L  P  R  G  G  S  V  L 
(VCAM-1  aa 9-12  [  ICAM-1 aa 11-18  ) 
Bg12 
P-2,  5' G GTG GAG ATC TAC TGG ACT CCA GAA CGG GTG GAA 3' 
V  E  I  "Y  W  T  P  E  K  V  E 
(VCAM-1  aa 86-89  I  ICAM-1 aa 84-90  ) 
Hind3 
P-3,  5' TCT CAA GCT TTT ACT GTT GAG ATC TCC CCT GG Y 
S  Q  "X  F  T  V  E  I  S  P  G 
(VCAM-1  aa -3-1  [  VCAM-1 aa 300-306  ) 
Bsu361 
P-4,  3' G  GAA GGA GTG GCA CAT GAC CTG AGG M'T CCT AGG TC 5' 
F  L  T  V  Y  W  T  P  K  D  P  E 
(  ICAM-1 aa 79-85  I  VCAM-1 aa 92-96  ) 
BspH1 
P-5,  3' CAC CAC GAC GAG GCA CCC CTC TTC GAG TAC TI~  TC 
V  V  L  L  R  G  E  K  L  M  K  S 
(  ICAM-1 aa 121-128  I  VCAM-1 aa 134-137) 
Bgl2 
P-6, 3' TGG TAG ATG TCG AAA GGC CGC ~  CTC TAG AGG GG 5' 
T  I  Y  S  F  P  A  P  E  I  S  P 
(  ICAM-1 aa 279-286  I VCAM-1 aa 302-305) 
Bsu361 
P-7, 3' CAC CTC GAG ATG AGT AAG GGA TIC CTA GGT C  5' 
V  E  L  Y  S  F  P  K  D  P  E 
(  VCAM-1 aa 385-394  [VCAM-1  aa 92-96  ) 
PCR synthesis for inserts for construct V/I-1 was primed with P-1 
and P-4; V/I-2, P-1 and P-5; WI-3, P-2 and P-6; V1/V4, P-3 and 
P-7. V6D/I-1 and -2 were made using the same insert as WI-1 
and -2, respectively,  cloned into VCAM-6D (clone 41) backbones 
instead of  VCAM-7D. After PCR synthesis  (performed  as described 
in reference 13), the insert fragments were digested with the ap- 
propriate restriction endonucleases  and gel purified. Backbone and 
insert fragments were ligated using New England Biolabs (Beverly, 
MA) ligase  and buffer, ethanol precipitated, and electroporated  into 
bacterial host strain MC1061/p3 using a gene pulser (Bio-Rad 
Laboratories, Richmond, CA). Clones were screened by PCR and 
restriction digests, and at least one isolate of each clone was se- 
quenced across cloning junctions and insert using a Sequenase kit 
(United States Biochemical Corp., Clevdand, OH). 
Cell-CellAdhesion Assays.  COS7 cells were transfected  by elec- 
troporation, as described (2), except 20/zg of phsmid was used 
and voltage was set at 300 V instead of 280 V. Cells were plated 
in 48-well plates for cell adhesion assays, and in 100-mm dishes 
for FACS  |  analysis  (Becton  Dickinson & Co., Mountain View, CA). 
Transfection dficiency ranged from 15 to 25% of surviving cells 
as estimated by FACS  |  analysis  (described  below). HUVECs were 
treated as described (2). Suspension cells (Ramos, Jurkat,  HL60, 
etc.) were labeled  for 20 rain with BCECF-AM (Molecular  Probes, 
Junction City, OR), as described  (23). Antibodies  were preincubated 
with transfected COS7 cells or HUVECs (anti-VCAM), or leuko- 
cytic cells (anti-CD18, anti-VLA-4), for 15 min at room tempera- 
turejust before the adhesion assay. Adhesion  assays  were performed 
by adding 0.15 ml oflabded suspension cells at 3 million cells per 
ml in RPMI/10% FCS to each well of transfected COS7 cells or 
HUVECs, which had been plated in 48-well  phtes and preincubated 
with 0.15 ml antibody at 2x  final  concentration or RPMI/10% 
FCS alone. The plates were incubated for 15 rain at 37~  except 
where noted, and then washed three or four times with 0.2 ml 
per well of HBSS with calcium and magnesium, added to the wells 
with a multichannel pipetter, and removed by inverting the plate 
and briefly shaking. After washing, cells were lysed with 0.12 ml 
1% NP-40, transferred to 96-well plates, and quantified using a 
Fluoroskan II plate reader (Labsystems, Inc., Shrewsbury, MA). 
Flow Cytometry.  Transfected COS  cells were removed from 
100-ram tissue culture dishes by incubation in HBSS/5 mM EDTA 
for 15 min at 37~  followed by vigorous pipetting. 3-5  x  10  s 
cell aliquots were incubated individually  in a volume of  0.1 ml with 
2/~g/ml mAbs to VCAM-1 or ICAM-1, or with polyclonal an- 
tiserum to VCAM-1 diluted 1:500, for 20 rain at room tempera- 
ture in PNF (PBS/0.1% sodium azide/2%  fetal bovine serum), 
washed two times with PNF, and incubated in a volume of 0.1 
ml for 20 rain at room temperature with 0.2 gg/ml secondary 
fluoresceinated Ab (rabbit anti-mouse Ig, or goat anti-rabbit Ig) 
in PNE Cells were then washed three times with PBS, suspended 
in PBS/1% formaldehyde,  stored dark at 4~  and analyzed using 
a FACStar  |  (Becton Dickinson & Co.). Number of cells (y axis) 
versus fluorescence  (FL1) was plotted, and the number of positive 
cells in each sample was determined as follows. COS7 cells trans- 
fected with CDM8 vector alone were stained in parallel with each 
mAb, and a marker was set on the FACS  |  histogram (Becton  Dick- 
inson & Co.) at the right edge of the peak, to exclude 99% of 
the negative ceils. The number of positive cells (to the right of 
this marker) was determined for each experimental transfection. 
Mean fluorescence  of these cells was determined, divided by 100, 
and multiplied by the number of positive cells to give the "expres- 
100  Endothelial  VCAM-1 Has Two Binding Sites for Leukocyte  VLA-4 sion index'; a number that represents total fluorescence  of  positive 
calls in the sample. The expression index therefore reflects both 
the number of positive cells and the mean fluorescence  of those 
cells, and directly varies with the total number of molecules ex- 
pressed in each sample. 
Results 
Ramos Cell Binding to VCAM-6D vs. VCAM-TD  Ramos 
is a B-lymphoblastoid cell line that expresses VLA-4 and thus 
binds to VCAM-1, but does not bind to other induced en- 
dothelial cell molecules such as ICAM-I or endothelial leu- 
kocyte adhesion molecule-1  (ELAM-1) (2). Thus it is a con- 
venient model line with which to assay VLA-4-dependent 
binding. Ramos cells bind to both VCAM-6D and -TD when 
these molecules are expressed  on COS cells that have been 
transfected with cDNA cloned into the vector CDM8. We 
had previously noted that binding to VCAM-7D was some- 
what greater than to VCAM-6D in transient transfection assays 
of a single preparation of each plasmid (13). To determine 
if this quantitative difference in binding activity was repro- 
ducible, several preparations of each plasmid were made, and 
dectroporated in paralld into COS cells. Repeated transfec- 
tions reveal that although expression  of the two plasmids is 
similar (Fig. 1 A), VCAM-7D, on average, binds significantly 
more cells per mm  ~ than does VCAM-6D (Fig. 1 B, no Ab). 
Binding to both 6 and 7 domain forms can be inhibited by 
the anti-VLA-4 mAb HP1/2, or by anti-VCAM-1 mAb 4B9 
(Fig.  t  B). 
Structural Similarities Of VCAM-1 and ICAM-I.  Although 
both mouse and rat VCAM-1 cDNAs have been cloned and 
characterized (24), the use of interspecies  chimeras was con- 
traindicated by our finding that both mouse and rat VLA-4 
bind to human VCAM-1,  suggesting that human VLA-4 
might well bind to mouse and/or rat VCAM-1 (L. Osborn, 
unpublished data, and 24). Thus interspecies chimeras would 
not allow us to map cell binding regions of the molecule 
by loss of function. Several features of ICAM-1 suggested 
it would be a suitable partner for VCAM-1 in chimeric con- 
structs. Although the genes encoding ICAM-1 and VCAM-1 
map to different chromosomes in both mouse and human, 
and so are not members of a typical closely linked multigene 
family like the Igs or sdectins (25,  26),  there are structural 
similarities between the two proteins that can probably be 
attributed  to  similarities  in  their  function.  ICAM-1  and 
VCAM-1 are, along with ICAM-2, the only known Ig su- 
perfamily molecules that bind integrin counter-receptors,  and 
might be expected to share structural features based on that 
common function. Amino acid sequence similarity analysis 
of VCAM-1 vs. the National Biomedical Research Founda- 
tion data base using the ALIGN program (Genetics Com- 
puter Group, Madison, WI) gave a higher score (10.1) for 
[CAM-1 than any other protein (2).  Upon alignment and 
calculation of percent identity, ICAM-1 and VCAM-1  are 
20-30%  identical in amino acid sequence.  When conserva- 
tive amino acid substitutions are taken into account, their 
similarity rises to 60-70%  (Fig. 2). Finally, ICAM-1 shares 
with VCAM-1 an unusual structural feature of the domains 
now known to be most important for cell binding: the first 
Ig domain of both molecules, and the fourth Ig domain of 
VCAM-I, have four rather than the usual two cysteine residues, 
and the position of the extra cysteine residues are conserved 
among all three domains exhibiting them (ICAM-1 domain 
1,  VCAM-1  domains 1 and 4)  (Fig.  2). 
Construction and Expression of VCAM-1/ICAM-1 Chimeric 
Constructs.  To choose suitable exchanges between the two 
sequences,  the first four domains of the ICAM-1 sequence 
were manuaUy aligned with VCAM-TD (Fig.  2). It should 
be noted that the details of this alignment are somewhat ar- 
bitrary  at many positions, and thus other alignments are pos- 
sible. VCAM-1/ICAM-1 (V/I or V6D-I) constructs were made 
using unique restriction endonuclease  sites in the VCAM-1 
plasmids, and PCR-generated fragments of ICAM-1. Of seven 
WI and V6D/I constructs made and tested, five were well 
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Figure 1.  (A) COS7 calls transfected  by electroporation 
with two (*)  or three preparations of cDNA encoding 
VCAM-7D (VC-7D) or VCAM-6D (VC-6D), analyzed  by 
flow  cytofluorometry  after  indirect  immunofluorescent  staining 
with anti-VCAM-1 mAb 4B9, which recognizes  domain 1 
of  both VCAM-6D and VCAM-7D. The number  of  cells  with 
fluorescent  intensity  (FL1) greater than that shown by 99% 
of control non-VCAM  transfectants  was determined  and mul- 
tiplied by the mean fluorescence  of these cells, to give the 
"expression  index",  which  directly  correhtes  with the number 
of VCAM-1 molecules  present. In each experiment, the ex- 
pression index  was averaged  for the two or three  phsmid  prepa- 
rations tested, and SD is indicated  by error bars. Data shown 
is from two experiments, representative  of data obtained  in 
four experiments.  Expression  index  may  be compared  within 
but not between experiments,  as time between staining  and 
fixing, and FACS  ~ analysis  varied  between experiments. (B) 
The transfected  COS7 cells described  in A above  were plated 
in paralld in 48-well plates at 3 ￿  10  s cells per well, grown 
to confluence  (48 h), and assayed  for binding  to fluorescently 
labeled Ramos cells, in the absence or presence of blocking 
mAbs to VCAM-1 (mAb 4B9) or to VLA-4  (mAb HP1/2). 
101  Osbom  et al. HindIII  EcoRV  SglII 
V  1  F^KIETTPESRYL^AQIGDSVSLTCSTTGCESPFF~WRTQ~DSPLNGKVTNE-GTTSTLTM~/PVSFGNEHSYL-CTATC-ESRKLEKGIQVEIY^S 
p  psxP  Sbhf  GsSV  fTCSTx  CapP  h  Iaz2L  K  Gppppf  fS  pEpS  C  ssC  aspp  Ksh  fpfY 
I  1  QTSVSP-SKVI  LPRGG•VLVT••T•-•DQPKL---LGIETPLFKKELLLPGNNR•vYE--LSNVQEDSQPMCYSNCPDGQSTAKTF-LTVY  W 
V2 
I  2 
V3 
I  3 
V  4 
I  4 
Bsu3  6I  BspHI 
F  ^  PKDPE  I  H-LSGP LEAGKP ITVKCSVADVYPFDRLE  ZDLLKGDH^LMKSQEFL-EDADRKSLETKSLEVTFTPVIED  I  -GKVLVCRAKL  H  I  ....  D  EMDSVPTVRQAVKELQVY 
Ppp  Ef  L  s  sGK  fTfbCpV  ss  P  spLpfsLLbGab  hKpp  f  E  Aa  p  TpsL  V  pD  G  shsCRspLpf  Eh  ps  xs  fp  h 
T  pERVELASLPSWQPVGKNLTLPEQVEGGAPRANLTVVLLRGEK  ELKREPAVGEPAEVT---TTVL  ......  VRRDHHGANFSCRTELDLRPQGLELFENTSAPYQLQTF 
I  Sp  KNTVI  SVNP  STKL-QE -GGSVT~4TCSSEGL -PAP  g  I  FWSKKLDNGNLQHLSGNATLTL  ....  IAMBM  ...... ED  SG-  -  IYVCEGVNL I  GKNRKEVEL  IVQ 
h  P  p  vsPps  L  E  sspsThsCS  aGL  PS  E  b  Ls  Gs  QbL  N  TfTh  hs  b  EDpG  hsC  sV  L  GppppEs  Vp 
VLPATP PQLVS  P  RV-L- -EVDTQGTVVC  SLDGLFPVS EAQV-  H-  LALGD  -QRL-  -NPTVTYGND 3F  SAKASVSVTAEDE  GTQRLTC -AVl  L  -GNQSQETLQTVTI 
SgIII 
EKPFTV^EISPG-PRIAAQIGDSVMLT~SVMGCESP~WRT-Q~D~PLSGKVR~EGTN~TLTLSPV~FENEHSYL~TVT~GHKK-LEKGIQV-ELYS  .  .  . 
p  s  pf  s  Phfs  GppV  fpCps  p  s  spPLs  Rsp  xP  aN  b3o  CxsT  L  b  Qs  EL  s 
YSFPAP  NVILTKPEVSE--GTEVTVKCEAH--PRA-KVTL•GVPAQPLGP--RAQ--LLLK-ATP--EDNGRSF•C•ATLEVAGQLIHKNQTRELRVLYG  ... 
a  -  acid  -  D,E 
f  -  aliphatic  -  L,I,V 
h  -  hydrophobic  -  L,I,V,M,Y,F 
o  -  aromatic  -  Y,F,W 
p  -  polar  -  K,R,H,D,E,Q,N,T,S 
s  -  small  -  A,G,S,T,V,N,D 
b  -  base  -  K,R,H 
x  -  hydroxyl  -  $,T 
Figure 2.  Alignment of VCAM-1 and ICAM-1 amino acid sequences, domains 1-4. The sequences were aligned by inspection. (1"1) VCAM-1 domain 
1; (11) ICAM-1 domain 1; etc. Domain boundaries  were assigned based on exon-intron borders  reported by Cybulsky et al.,  (15). Restriction sites 
of VCAM-1 that were used to make chimeric constructs (see Fig. 3) are indicated at the site where the amino acid sequences of VCAM-1 and ICAM-1 
are joined. The restriction  sites fall near but not necessarily at  the junction codons  (see Materials and Methods  for details). 
Binding  mAb4B9  mAb ED11  mAb GH12  mAb GE4 
to Ramos  bind/block  bind/block  bind/block  bind/block 
A  I  ~,~ I  ~,  I  ,~:l:~il  D~II~,.;14,1  ~CAM~  o  -/-  -/-  -,-  ''' 
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Figure 3.  Schematic diagram  of 
parental  and  chimeric constructs, 
adhesion to Ramos cells, and bind- 
ing and blocking of adhesion  by 
anti-VCAM-1  mAbs.  (A) ICAM- 
1, VCAM-7D (clone 1Ell, (13), and 
chimeric  VCAM/  ICAM-1  con- 
structs  V/I-l,  -2,  and  -3.  (Open 
boxes) VCAM-1 derived sequences 
are indicated. (S@p/ed  baxes) ICAM-1 
derived sequences. CDM8 vector se- 
quences are not shown. Restriction 
endonuclease  sites: HindlII,  H3; 
EcoR.V, RV;  BgllI, Bg2;  EcoRI, 
R1; Bsu36I, Bsu36; BspHI, BspH1. 
(B)  VCAM-6D  (VCAM/CDM8, 
(2) and chimeric constructs V6D/I- 
1 and -2. (C) Construct V1/V4, in 
which VCAM-6D domain 1 is re- 
placed  by  VCAM-7D  domain  4 
(hatched box). At right, binding of 
each construct to Ramos cells, as a 
percentage  relative to VCAM-7D, 
is indicated. Results are averages of 
triplicate determinations  from one 
experiment, representative of at least 
three  experiments.  Two indepen- 
dently isolated clones of each con- 
struct except WI-2 and V1/V4 were tested,  and found to be the same in expression and cell binding.  Expression  of each construct was determined 
in every experiment  by FACS  |  using polyclonal anti-VCAM serum as primary antibody,  as described in legend to Fig. 1 and Materials and Methods, 
and differences in expression were found to be negligible, as correction  for expression changed raw data by <3%. Ability of mAbs 4B9, EDll, GH12, 
and GE4 to bind to each construct (assessed by FACS|  and to block Ramos cell adhesion is summarized  as plus or minus,  as results were essentially 
either positive or negative in all cases, except mAb ED11 blocking of Ramos binding to VCAM-7D, which was partial  (about  50%) at  the single 
concentration  tested  (5 ~g/ml). 
102  Endothelial  VCAM-1 Has Two Binding  Sites for Leukocyte VLA-4 expressed (schematically  diagrammed in Fig. 3, A and B) when 
transfected into COS cells, assessed by FACS  |  analysis after 
staining with polyclonal antiserum to VCAM-1. In constructs 
WI-1 and WI-2, most of domain 1, or most of domain 1 
and the first half of domain 2, are replaced by ICAM-1  se- 
quence. In construct WI-3, domains 2 and 3, and small por- 
tions of domains 1 and 4, are replaced by ICAM-1 sequence. 
Two constructs,  in which the regions between the Bsu361 
and BspH1, and the BspH1 and EcoR1 sites were replaced, 
were not well expressed, and were not analyzed further. 
Blocking mAb 4B9 Binds to Domain 1.  Blocking antibodies 
have often proved useful for defining binding sites of adhe- 
sion molecules, as the epitope for the blocking mAb usually 
maps physically near, though not exactly to, the amino acids 
involved in binding (27, 28). Anti-VCAM-1 mAb 4B9 blocks 
binding of VLA-4-bearing cells to VCAM-6D or -7D. As 
mentioned above, recombinant  soluble  domains  1+2  of 
VCAM-1 can bind both cells and mAb 4B9 (C. Hession and 
K. Lobb, unpublished data). Chimeric constructs WI-1 and 
-2 are not stained by mAb 4B9, indicating that the epitope 
to which 4B9 binds requires domain 1 for recognition (Fig. 
3). 4B9 does stain construct WI-3, confirming that domain 
1 contains  the 4B9 epitope. 
Ramos  Cell Binding  to  VCAM-1/ICAM-1  Chimeric  Con- 
structs.  Although constructs WI-1 and WI-2 do not bind 
mAb 4B9, both bind Ramos cells at about 30% of the level 
seen with intact VCAM-7D (Fig. 3). This adhesion is VLA- 
4/VCAM-1 mediated, as anti-VLA-4 mAb HP1/2 completely 
inhibited the interaction, while a blocking antibody to the 
ICAM-1 pathway (mAb 60.3) did not effect cell binding (data 
not shown). Construct WI-3 binds Ramos cells weakly but 
measurably, at about 10% of the level seen with intact VCAM- 
7D. mAb 4B9, against domain 1 of  VCAM-1, and anti-VLA-4 
mAb HP1/2 inhibits Ramos cell adhesion to WI-3 completely, 
while mAb 60.3 has no effect (data not shown). 
Ramos Cells Bind to Two Separate Regions of VCAM-I, In- 
volving Domains 1 and 4.  To determine if cell binding to con- 
structs WI-1 and V/I-2 was due to residual portions of the 
domain 1-dependent binding site, or to domain 4, which is 
structurally similar to domain 1, constructs analogous to 1 
and 2 were made, using VCAM-6D instead of-7D as the 
parent plasmid  (Fig. 3 B). These constructs were well ex- 
pressed in COS cells as measured by polyclonal antiserum 
staining, but were unable to bind Ramos cells (Fig. 3). Thus 
the binding of Ramos cells to constructs 1 and 2 requires 
the presence of domain 4. 
To confirm this interpretation,  construct V1/V4, in which 
domain 4 of VCAM-7D was substituted for domain 1 of 
VCAM-6D (Fig. 3 C), was made. V1/V4 binds Ramos cells 
as well as does the parent VCAM-6D plasmid (Fig. 3), indi- 
cating that domain 4 can indeed bind cells, in the absence 
of domain 1. 
How can this result be reconciled with the fact that mAb 
4B9, which binds  to domain 1 but not to domain 4, can 
completely inhibit binding of Ramos cells to VCAM-7D? 
Steric hindrance of  domain 4 activity is one possible explana- 
tion (see below).  It is also possible that binding of 4B9 to 
domain 1 perturbs the structure of the molecule so that do- 
main 4 is no longer in the proper conformation to bind cells. 
mAbs that Block Domain 4-dependent Cell Binding.  BALB/c 
mice were immunized with recombinant soluble VCAM-1 
(7D) and used to make hybridomas. Three mAbs were pro- 
duced that recognize VCAM-7D but not VCAM-6D, indi- 
cating that they recognize  a domain 4-dependent epitope 
(C. D. Benjamin and I. Dougas, unpublished data, and Fig. 
3).  These antibodies,  ED11, GH12,  and GE4,  were tested 
for ability to stain and to block Ramos cell binding to con- 
structs exhibiting domain 4-dependent binding (Fig. 3). mAb 
GE4 stains WI-1, -2, and -3, does not stain V1/V4, and does 
not block Ramos cell binding to any of these constructs, mAb 
ED11 stains and blocks WI-1 and -2, but not -3 or V1/V4. 
This antibody also partially blocks Ramos cell binding to 
VCAM-7D. mAb GH12 stains and blocks WI-1 and -2, and 
V1/V4, but not WI-3. It did not block Ramos cell binding 
to VCAM-7D at the single concentration tested. Each anti- 
body recognizes a different subset of constructs,  indicating 
that each of the three antibodies recognizes distinct epitopes, 
and two are capable of blocking domain 4-dependent adhe- 
sion of VLA-4 to VCAM-1. This new class of anti-VCAM-1 
blocking antibodies provides unique reagents for ensuring 
complete inhibition of VCAM-l-mediated adhesion. 
Inhibition of R amos Cell Binding  to Cytokine-activated En- 
dothelial Cells by Domains I- and 4-dependent mAbs.  To deter- 
mine if domain 4-dependent mAbs ED11 or GH12  were 
capable of  blocking adhesion to VCAM-1 on endothelial cells 
(which is predominantly VCAM-7D), HUVECs were treated 
with 20 ng/ml human recombinant TNF for 4, 24, 48, or 
72 h, and binding of Ramos cells and ability of antibodies 
to block binding were measured (Fig. 4 A-D). mAb GH12 
did not block binding reliably at the single concentration tested 
(10 #g/ml), but mAb EDll blocked more than 80% of Ramos 
cell binding to induced endothelial  cells at all time points 
tested. Jurkat (a T cell leukemia line) binding was tested in 
parallel at 24 h after induction. This line binds more avidly, 
yielding more than four times as many cells bound per mm  2 
than Ramos (data not shown). In contrast to Ramos, mAb 
EDll blocked Jurkat by only about 20%, although, as we 
previously reported, 4B9 blocked binding of both cell lines 
by >90% (data not shown). This result,  coupled with the 
inability of EDll to completely block binding of Ramos to 
VCAM-7D expressed on COS cells, suggests that the effect 
of ED11 on domain 1-dependent binding is variable, and may 
depend on the density of receptor and counter-receptor,  and 
perhaps the activation state of the VLA-4-bearing cell (see 
below). 
Overall, the data strongly suggest that although the two 
cell binding sites of VCAM-1 (domains 1- and 4-dependent) 
can be separated and remain functional,  antibodies to each 
can interfere with cell binding to the other. This is so even 
though the antibodies do not cross-react with each other's 
binding sites (shown by the differential antibody binding data 
to constructs, Fig. 3, and conventional cross-blocking studies 
with labeled antibodies, C. D. Benjamin and I. Dougas, un- 
published data). Steric hindrance might account for this, as 
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Figure 4.  Ability  of anti-VCAM-1 mAbs  4139, GH12, and EDll to block 
Ramos cell adhesion to TNF-activated endothelial cells. 20 ng/ml recom- 
binant human TNF was added to confluent HUVECs in 48-well clusters 
at the indicated time before adhesion assay: (A) 4 h; (B) 24 h; (C) 48 h; 
and (/9) 72 h; note that x axes are not equivalent, mAbs were added to 
the binding assay to a final concentration of 10 #g/ml, as described in 
Materials and Methods. Data is from a single experiment, representative 
of two. 
we suggested for the similarly surprising  ability of 4B9 to 
inhibit completely binding to VCAM-7D. The arrangement 
of VCAM-1 domains has not yet been determined by elec- 
tron microscopy. However, even if domains 1 and 4 are max- 
imally distant from each other, an antibody molecule or Fab 
fragment is large enough to span the distance between the 
two, so that an antibody bound to domain 1 could overhang 
and thus sterically hinder access to domain 4, provided its 
binding orientation was suitable. Similarly, an antibody bound 
to domain 4 in the correct orientation  could overhang do- 
main 1. We might then expect to find four types of VCAM-1 
blocking antibodies:  (a) domain  1 binders that block only 
domain 1; (b) domain 4 binders that block only domain 4; 
(c) domain 1 binders that block both domains 1 and 4; and 
(d) domain 4 binders that block both domains 4 and 1. Sev- 
eral partially blocking anti-VCAM-1 mAbs are found in the 
literature,  and may belong to class 1 or 2 above (e.g., mAb 
2G6 [29], and mAb El/6 [1]). The completely blocking mAb 
4B9 clearly belongs to class  3, while the case for EDll  is 
still unclear; perhaps it is a weak member of class 4. Attrac- 
tive as this  simple model of steric hindrance  may be, it is 
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Figure 5.  Temperature  sensitivity  of VCAM-1/VLA-4  binding. Ramos 
cell adhesion to COS7 cell transfectants was assayed  at 4, 25, and 37~ 
also possible that binding of the antibody to one domain can 
perturb the structure of another domain of the molecule. It 
is clear that  considerable caution must be used in drawing 
conclusions based on antibody blocking data in this system. 
Both Domains 1- and 4-dependent Binding of VCAM-I to Cells 
Is Temperature  Sensitive.  Recently, reports from other labora- 
tories have described assays of VCAM-l-dependent binding 
under conditions of reduced temperature,  in rabbit (15) and 
in mouse (10).  This was puzzling,  as previously we noted 
that binding  to VCAM-1 of the VLA-4-bearing  cell lines 
we have tested (Ramos, Jurkat,  U937,  THP1,  and HL60) 
is temperature sensitive;  chilling cells to 4~  just before and 
during adhesion assay completely abolished VCAM-l-depen- 
dent binding,  although  ELAM-l-transfected  controls bind 
HL60 cells equally well at 4,  25,  or 37~  Because many 
of our early assays on transfected cells were performed using 
VCAM-6D,  we tested VCAM-6D,  -7D,  and our chimeric 
constructs, as well as induced endothelial cells, for adhesion 
to various VLA-4-bearing leukocytic cell lines at reduced tem- 
perature, to determine if cold has differential effects on binding 
mediated by the two sites.  Ramos cell binding to domains 
1-, 4-, and 1- and 4-dependent constructs is abolished at 4~ 
(Fig.  5).  VCAM-l-dependent  binding  of Ramos, Jurkat, 
THP1, and HL60 cells to endothelial cells at 4, 24, 48, or 
72 h after TNF induction is also abolished at 4~  (data not 
shown). Aside from the rather unlikely possibility of species 
variation, the apparent contrast of our results with those cited 
above might be caused by a difference in VLA-4 conforma- 
tion or activation state on the surface of the leukocytic cells 
tested. A number of published reports suggest that different 
affinity states of VLA-4 exist (29-31). Perhaps the temperature- 
sensitive cell lines  all carry a low affinity form of VLA-4, 
which contrasts to a relatively temperature insensitive, high 
affinity form produced by posttranslational charges in the con- 
formation of VLA-4, similar  to that reported for the B2 inte- 
grin LFA-1 (32, 33). Future experiments should be able to 
resolve this issue. 
Evidence for the Evolutionary Origin and Functional Utility 
of Bivalent VCAM-7D.  It is immediately apparent that the 
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result of an intergenic duplication event during the evolu- 
tionary history of the gene (Fig.  6; 2,  11-15).  Duplication 
of the adhesive portion of the molecule might well result 
in a molecule with potential for bivalent interaction with 
its counter-receptor, if the functional region was completely 
duplicated and if the proximal site was not sterically blocked 
from access to the counter-receptor by the new portion of 
the molecule. However, if the function of one or the other 
binding sites were not of any utility in the function of the 
molecule, one binding site would be expected to lose func- 
tion during evolution, as it diverged because of random mu- 
tation. This is clearly not the case for VCAM-1. Although 
the intergenic duplication must have occurred before the mam- 
malian radiation (about 200 million years ago), as it is also 
found in the rat and mouse genes (24),  we have shown that 
both sites are still fully functional, in the human species. A 
closer examination of the amino acid similarity between the 
duplicated domains reveals that the domains most crucial to 
binding function, 1 and 4, are 73% similar,  while domains 
2 and 5, and 3 and 6, are each only 59% similar to each other 
(Fig. 6). This strongly suggests that there is increased selec- 
tive demand for maintenance of the structures of domains 
1 and 4, compared with the less functionally pressured do- 
mains 2,  3,  5,  and 6.  It seems likely that the bivalence of 
VCAM-7D provides increased avidity for its counter-receptor 
(as suggested by Fig.  1), and that this is advantageous to the 
physiology of the organism. The additional domain may of 
course also play some further role in adhesion, endothelial 
transmigration of mononuclear leukocytes, or B cell devel- 
opment. The reagents described here should provide valu- 
able tools for determining additional functions of the two 
binding sites. 
Discussion 
Other adhesion molecules have been shown to have more 
than one binding site for distinct counter-receptors, or non- 
homologous binding sites for a single counter-receptor. For 
example, ICAM-1 has separate binding sites for LFA-1 and 
Mac-1 (34), fibronectin has separate binding sites for VLA-5 
and for VLA-4 (35),  and fibrinogen has two dissimilar sites 
that bind the integrin IIb/IIIa.  VCAM-1 is the first mole- 
cule found to have two homologous binding sites for a single 
receptor, VLA-4, generated by an intergenic duplication. Pos- 
sible  arenas for functional interplay include signaling and 
binding.  For example, VCAM-1 can cause proliferation of 
T cells through domain 1-3 in the presence of a second signal 
(36, 37).  It is not yet known whether domain 4-6 also has 
this capacity. 
Recent experiments from Vonderheide and Springer (38) 
also  have suggested the existence of dual binding sites  in 
VCAM-1, based on the properties of mAb E1/6, which can 
completely inhibit binding of Ramos cells to our VCAM-6D 
construct, but only partially to VCAM-7D.  These authors 
also suggest that an additional c~4 integrin counter-receptor 
is present on stimulated endothelium, based on inability of 
mAb 4B9 to inhibit completely binding of two cell lines to 
HUVEC,  although  the anti-c~4 mAb  HP2/1  can  inhibit 
completely. It will be interesting to follow future experiments 
aimed at defining this novel receptor. 
VCAM-6D,  a minor form of VCAM-1 lacking domain 
4 because of alternate splicing, remains mysterious with re- 
gard to biological significance.  It may be caused simply by 
an occasional error in splicing resulting from skipping of the 
exon encoding domain 4.  However, if differential distribu- 
tion or regulation of these two forms is found, VCAM-6D 
could provide clues as to the physiological significance of the 
two binding domains. 
In summary, VCAM-1 has been shown to have two func- 
tional binding sites for VLA-4, and antibodies that block this 
site have been described. All physiological and pathological 
processes involving VCAM-1, including B cell development, 
leukocyte activation  and  recruitment,  atherosclerosis,  and 
metastasis, are potentially affected by the additional site, and 
it should be considered when using anti-VCAM-1 antibodies 
to block this adhesion pathway. The discovery of the new 
site, and blocking mAbs to domain 4 of VCAM-1, will pro- 
vide valuable new tools for dissecting the mechanism and 
biology  of the  VCAM-1/VLA-4  adhesion  and  signaling 
pathway, and for implementing therapeutic strategies based 
on stimulation or suppression of this pathway. 
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